PRODUCT INFORMATION

C-02

Item No. 39384

CAS Registry No.:	3033812-84-6
Formal Name:	1-[(2,4-dichlorophenyl)methyl]-N-[4-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]<wbr/>amino]butyl]-1H-indazole-3-carboxamide
MF:	$C_{32}H_{28}Cl_2N_6O_5$
FW:	647.5
Purity:	≥95%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥3 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

C-02 is supplied as a solid. A stock solution may be made by dissolving the C-02 in the solvent of choice, which should be purged with an inert gas. C-02 is soluble in ethanol and methanol.

Description

C-02 is a proteolysis-targeting chimera (PROTAC) composed of the hexokinase inhibitor lonidamine (Item No. 14640) linked to the cereblon ligand thalidomide (Item No. 14610).[1] It induces degradation of hexokinase 2 in 786-O and PANC-1 cells when used at a concentration of 20 µM. C-02 is cytotoxic to 786-O, 4T1, PANC-1, HGC-27, and MCF-7 cancer cells (IC_{50}s = 34.07, 5.08, 31.53, 6.11, and 21.65 µM, respectively). It reduces the extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) in 4T1 cells, indicating inhibition of glycolysis and mitochondrial damage, respectively, when used at a concentration of 20 µM. *In vivo*, C-02 (50 mg/kg) reduces tumor volume and induces intratumoral cytokine accumulation and pyroptosis in a 4T1 murine mammary carcinoma model.

Reference

1. Sang, R., Fan, R., Deng, A., *et al.* Degradation of hexokinase 2 blocks glycolysis and induces GSDME-dependent pyroptosis to amplify immunogenic cell death for breast cancer therapy. *J. Med. Chem.* **66(13)**, 8464-8483 (2023).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM